| [X]            | Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 |
|----------------|-----------------------------------------------------------------------------------------|
|           |                                                                                    |
|           | For the quarterly period ended September 30, 2009                                       |
|           |                                                                                    |
| [  ] | Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934        |
|           |                                                                                    |
|           | For the transition period from __________ to __________                       |
|           |                                                                                    |
|           | Commission File Number: 000-52703                                                       |

| Nevada                                                         | 20-4939361                        |
|----------------------------------------------------------------|-----------------------------------|
| (State or other jurisdiction of incorporation or organization) | (IRS Employer Identification No.) |

| 1461 A. First Avenue, Suite 360 New York, NY |
|----------------------------------------------|
| (Address of principal executive offices)     |

| (646) 845-1920                                                                           |
|------------------------------------------------------------------------------------------|
| (Registrant’s telephone number)                                                    |
|  _______________________________________________________________                    |
| (Former name, former address and former fiscal year, if changed since last report)  |

| [ ] Large accelerated filer Accelerated filer | [ ] Non-accelerated filer |
|-----------------------------------------------|---------------------------|
| [X] Smaller reporting company                 |                      |

----

Table of Contents

|                                          | TABLE OF CONTENTS                                                                           |   Page |
|-----------------------------------------------|---------------------------------------------------------------------------------------------|------------------|
| PART I – FINANCIAL INFORMATION     |
| Item 1:                                       | Financial Statements                                                                        | 3                |
| Item 2:                                       | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 4                |
| Item 3:                                       | Quantitative and Qualitative Disclosures About Market Risk                                  | 10               |
| Item 4T:                                      | Controls and Procedures                                                                     | 10               |
|  PART II – OTHER INFORMATION  |
| Item 1:                                       | Legal Proceedings                                                                           | 11               |
| Item 1A:                                      | Risk Factors                                                                                | 11               |
| Item 2:                                       | Unregistered Sales of Equity Securities and Use of Proceeds                                 | 11               |
| Item 3:                                       | Defaults Upon Senior Securities                                                             | 11               |
| Item 4:                                       | Submission of Matters to a Vote of Security Holders                                         | 11               |
| Item 5:                                       | Other Information                                                                           | 11               |
| Item 6:                                       | Exhibits                                                                                    | 11               |

----

Table of Contents

Item 

| Our financial statements included in this Form 10-Q are as follows:  |
|---------------------------------------------------------------------------|
| F-1                                                                       | Balance Sheets as of September 30, 2009 (unaudited) and December 31, 2008 (audited); |
| F-2                                                                       | Statements of Operations for the three  and nine months ended September 30, 2009 and 2008, and for the period from July 1, 2009 (inception of current operations) to September 30, 2009 (unaudited); |
| F-3                                                                       | Statements of Cash Flows for the nine months ended September 30, 2009 and 2008, and for the period from July 1, 2009 (inception of current operations) to September 30, 2009 (unaudited); |
| F-4                                                                       | Notes to Financial Statements; |

----

Table of Contents

GENOVA 

|                                                                                                                                         | September 30,2009$ |      | December 31,2008$ |
|----------------------------------------------------------------------------------------------------------------------------------------------|--------------------|-----------|-------------------|
|                                                                                                                                         | (unaudited)        |      | (audited)         |
| ASSETS                                                                                                                                       |               |      |              |
|                                                                                                                                         |               |      |              |
| Current assets                                                                                                                               |               |      |              |
|                                                                                                                                         |               |      |              |
| Cash                                                                                                                                         |               | 25,204    |              |   | 21,220 |
| Due from director (Note 5)                                                                                                                   |               | 4,413     |              |   | – |
|                                                                                                                                         |               |      |              |   |   |
| Total current assets                                                                                                                         |               | 29,617    |              |   | 21,220 |
|                                                                                                                                         |               |      |              |   |   |
| Intangible assets (Note 4)                                                                                                                   |               | 81,257    |              |   | – |
| Long-term assets of discontinued operations                                                                                                  |               | –   |              |   | 38,734 |
|                                                                                                                                         |               |      |              |   |   |
| Total assets                                                                                                                                 |               | 110,874   |              |   | 59,954 |
|                                                                                                                                         |               |      |              |   |   |
| LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)                                                                                         |               |      |              |   |   |
|                                                                                                                                         |               |      |              |   |   |
| Current liabilities                                                                                                                          |               |      |              |   |   |
|                                                                                                                                         |               |      |              |   |   |
| Accounts payable                                                                                                                             |               | 21,073    |              |   | 14,077 |
| Accrued liabilities                                                                                                                          |               | 2,906     |              |   | 4,286 |
| Due to related parties (Note 5)                                                                                                              |               | 36,673    |              |   | 31,272 |
| Current liabilities of discontinued operations                                                                                               |               | –   |              |   | 26,717 |
|                                                                                                                                         |               |      |              |   |   |
| Total current liabilities                                                                                                                    |               | 60,652    |              |   | 76,352 |
|                                                                                                                                         |               |      |              |   |   |
| Long-term liabilities of discontinued operations                                                                                             |               | –   |              |   | 19,282 |
|                                                                                                                                         |               |      |              |   |   |
| Total liabilities                                                                                                                            |               | 60,652    |              |   | 95,634 |
|                                                                                                                                         |               |      |              |   |   |
| Stockholders’ equity (deficit)                                                                                                         |               |      |              |   |   |
|                                                                                                                                         |               |      |              |   |   |
| Preferred stockAuthorized: 10,000,000 shares, par value US$0.001 Issued and outstanding: Nil shares                                     |               | –   |              |   | – |
|                                                                                                                                         |               |      |              |   |   |
| Common stockAuthorized: 990,000,000 shares, par value US$0.00001Issued and outstanding: 307,296,125 shares (2008 – 300,000,000 shares) |               | 3,446     |              |   | 3,364 |
|                                                                                                                                         |               |      |              |   |   |
| Additional paid-in capital                                                                                                                   |               | 223,363   |              |   | 129,436 |
|                                                                                                                                         |               |      |              |   |   |
| Accumulated other comprehensive loss                                                                                                         |               | –   |              |   | (855) |
|                                                                                                                                         |               |      |              |   |   |
| Accumulated deficit                                                                                                                          |               | (180,800) |              |   | (167,625) |
|                                                                                                                                         |               |      |              |   |   |
| Retained earnings during the development stage                                                                                               |               | 4,213     |              |   | – |
|                                                                                                                                         |               |      |              |   |   |
| Total stockholders’ equity (deficit)                                                                                                   |               | 50,222    |              |   | (35,680) |
|                                                                                                                                         |               |      |              |   |   |
| Total liabilities and stockholders’ equity (deficit)                                                                                   |               | 110,874   |              |   | 59,954 |

----

Table of Contents

GENOVA 

|                                          | Three Months EndedSeptember 30, |        | Nine Months EndedSeptember 30, |   | Accumulated from July 1, 2009 to September 30, |
|-----------------------------------------------|---------------------------------|-------------|--------------------------------|--------|------------------------------------------------|
|                                          | $                               | 2009        |                           | $      | 2008                                           |   | $ | 2009 |   | $ | 2008 |   | $ | 2009 |
|                                          |                            |        |                           |   |                                           |   |   |   |   |   |   |   |   |   |
| Revenue                                       |                            | –     |                           |   | –                                        |   |   | – |   |   | – |   |   |   |
|                                          |                            |        |                           |   |                                           |   |   |   |   |   |   |   |   |   |
| Expenses                                      |                            |        |                           |   |                                           |   |   |   |   |   |   |   |   |   |
|                                          |                            |        |                           |   |                                           |   |   |   |   |   |   |   |   |   |
| Professional fees                             |                            | (187)       |                           |   | 1,576                                          |   |   | 13,868 |   |   | 4,906 |   |   | (187) |
| Transfer agent and filing fees                |                            | 1,482       |                           |   | 7,992                                          |   |   | 13,752 |   |   | 7,992 |   |   | 1,482 |
|                                          |                            |        |                           |   |                                           |   |   |   |   |   |   |   |   |   |
| Total expenses                                |                            | 1,295       |                           |   | 9,568                                          |   |   | 27,620 |   |   | 12,898 |   |   | 1,295 |
|                                          |                            |        |                           |   |                                           |   |   |   |   |   |   |   |   |   |
| Net loss before other income                  |                            | (1,295)     |                           |   | (9,568)                                        |   |   | (27,620) |   |   | (12,898) |   |   | (1,295) |
|                                          |                            |        |                           |   |                                           |   |   |   |   |   |   |   |   |   |
| Other income                                  |                            |        |                           |   |                                           |   |   |   |   |   |   |   |   |   |
|                                          |                            |        |                           |   |                                           |   |   |   |   |   |   |   |   |   |
| Foreign exchange gain                         |                            | 5,508       |                           |   | –                                        |   |   | 3,362 |   |   | – |   |   | 5,508 |
|                                          |                            |        |                           |   |                                           |   |   |   |   |   |   |   |   |   |
| Net income (loss) from continuing operations  |                            | 4,213       |                           |   | (9,568)                                        |   |   | (24,258) |   |   | (12,898) |   |   | 4,213 |
|                                          |                            |        |                           |   |                                           |   |   |   |   |   |   |   |   |   |
| Discontinued operations (Note 3)              |                            | –     |                           |   | (16,743)                                       |   |   | 15,296 |   |   | (14,415) |   |   | – |
|                                          |                            |        |                           |   |                                           |   |   |   |   |   |   |   |   |   |
| Net income (loss) for the period              |                            | 4,213       |                           |   | (26,311)                                       |   |   | (8,962) |   |   | (27,313) |   |   | 4,213 |
|                                          |                            |        |                           |   |                                           |   |   |   |   |   |   |   |   |   |
| Other comprehensive income (loss)             |                            |        |                           |   |                                           |   |   |   |   |   |   |   |   |   |
|                                          |                            |        |                           |   |                                           |   |   |   |   |   |   |   |   |   |
| Foreign currency translation adjustments      |                            | (848)       |                           |   | 392                                            |   |   | 855 |   |   | (19) |   |   | (848) |
|                                          |                            |        |                           |   |                                           |   |   |   |   |   |   |   |   |   |
| Comprehensive income (loss)                   |                            | 3,365       |                           |   | (25,919)                                       |   |   | (8,107) |   |   | (27,332) |   |   | 3,365 |
|                                          |                            |        |                           |   |                                           |   |   |   |   |   |   |   |   |   |
| Net loss per share, basic and diluted         |                            |        |                           |   |                                           |   |   |   |   |   |   |   |   |   |
| Continuing operations                         |                            | –     |                           |   | –                                        |   |   | – |   |   | – |   |   |   |
| Discontinued operations                       |                            | –     |                           |   | –                                        |   |   | – |   |   | – |   |   |   |
|                                          |                            |        |                           |   |                                           |   |   |   |   |   |   |   |   |   |
|                                          |                            | –     |                           |   | –                                        |   |   | – |   |   | – |   |   |   |
|                                          |                            |        |                           |   |                                           |   |   |   |   |   |   |   |   |   |
| Weighted average number of shares outstanding |                            | 312,503,489 |                           |   | 300,000,000                                    |   |   | 312,340,919 |   |   | 300,000,000 |   |   |   |

----

Table of Contents

GENOVA 

|                                                                                            | NineMonths EndedSeptember 30, |     | NineMonths EndedSeptember 30, |   | Accumulated from July 1, 2009 to September 30, |
|-------------------------------------------------------------------------------------------------|-------------------------------|----------|-------------------------------|--------|------------------------------------------------|
|                                                                                            | $                             | 2009     |                          | $      | 2008                                           |   | $ | 2009 |
|                                                                                            |                          |     |                          |   |                                           |   |   |   |
| Operating activities                                                                            |                          |     |                          |   |                                           |   |   |   |
|                                                                                            |                          |     |                          |   |                                           |   |   |   |
| Net income (loss) from continuing operations for the period                                     |                          | (24,258) |                          |   | (12,898)                                       |   |   | 4,213 |
|                                                                                            |                          |     |                          |   |                                           |   |   |   |
| Changes in operating assets and liabilities:                                                    |                          |     |                          |   |                                           |   |   |   |
|                                                                                            |                          |     |                          |   |                                           |   |   |   |
| Accounts payable and accrued liabilities                                                        |                          | 5,616    |                          |   | 6,150                                          |   |   | (1,219) |
|                                                                                            |                          |     |                          |   |                                           |   |   |   |
| Net cash provided by (used in) operating activities                                             |                          | (18,642) |                          |   | (6,748)                                        |   |   | 2,994 |
|                                                                                            |                          |     |                          |   |                                           |   |   |   |
| Financing activities                                                                            |                          |     |                          |   |                                           |   |   |   |
|                                                                                            |                          |     |                          |   |                                           |   |   |   |
| Advances from related parties                                                                   |                          | 18,554   |                          |   | 5,267                                          |   |   | – |
| Repayment of related party loans                                                                |                          | (9,000)  |                          |   | –                                        |   |   | (5,826) |
|                                                                                            |                          |     |                          |   |                                           |   |   |   |
| Net cash provided by financing activities                                                       |                          | 9,554    |                          |   | 5,267                                          |   |   | (5,826) |
|                                                                                            |                          |     |                          |   |                                           |   |   |   |
| Net cash provided by discontinued operations                                                    |                          | 12,217   |                          |   | 9,807                                          |   |   | – |
|                                                                                            |                          |     |                          |   |                                           |   |   |   |
| Effect of exchange rate changes on cash                                                         |                          | 855      |                          |   | (19)                                           |   |   | (848) |
|                                                                                            |                          |     |                          |   |                                           |   |   |   |
| Change in cash                                                                                  |                          | 3,984    |                          |   | 8,307                                          |   |   | (3,680) |
|                                                                                            |                          |     |                          |   |                                           |   |   |   |
| Cash, beginning of period                                                                       |                          | 21,220   |                          |   | 16,275                                         |   |   | 28,884 |
|                                                                                            |                          |     |                          |   |                                           |   |   |   |
| Cash, end of period                                                                             |                          | 25,204   |                          |   | 24,582                                         |   |   | 25,204 |
|                                                                                            |                          |     |                          |   |                                           |   |   |   |
| Non-cash investing and financing activities:                                                    |                          |     |                          |   |                                           |   |   |   |
| Common stock issued for the acquisition of intangible assets                                    |                          | 81,257   |                          |   | –                                        |   |   | – |
| Net liabilities of travel business assumed by a director recorded as additional paid-in capital |                          | 12,753   |                          |   | –                                        |   |   | 12,753 |
|                                                                                            |                          |     |                          |   |                                           |   |   |   |
| Supplemental disclosures:                                                                       |                          |     |                          |   |                                           |   |   |   |
| Interest paid                                                                                   |                          | –  |                          |   | –                                        |   |   | – |
| Income taxes paid                                                                               |                          | –  |                          |   | –                                        |   |   | – |

----

Table of Contents

GENOVA 

| 1.   | Basis of Presentation |
|----------------|-----------------------|

| 2.   | Recent Accounting Pronouncements |
|----------------|----------------------------------|

----

Table of Contents

GENOVA 

| 2.   | Recent Accounting Pronouncements (continued) |
|----------------|----------------------------------------------|

| 3.   | Discontinued Operations |
|----------------|-------------------------|

|                                     | $      |     |
|------------------------------------------|--------|----------|
|                                     |   |     |
| Accounts receivable                      |   | 6,165    |
| Property and equipment                   |   | 16,467   |
| Website development costs                |   | 592      |
| Travel agency bond                       |   | 15,000   |
| Accounts payable and accrued liabilities |   | (26,030) |
| Loan payable                             |   | (19,861) |
| Due to director                          |   | (5,086)  |
|                                     |   |     |
|                                     |   | (12,753) |

|                       | $      |     |
|----------------------------|--------|----------|
|                       |   |     |
| Revenue, net               |   | 69,591   |
| Automotive                 |   | (7,822)  |
| Depreciation               |   | (6,674)  |
| General and administrative |   | (12,732) |
| Interest                   |   | (1,254)  |
| Wages and benefits         |   | (25,813) |
|                       |   |     |
| Net income for the period  |   | 15,296   |

----

Table of Contents

GENOVA 

| 4.   | Intangible Assets |
|----------------|-------------------|

| 5.   | Related Party Transactions |
|----------------|----------------------------|

| a)   | As at September 30, 2009, the Company is owed $4,413 from (December 31, 2008 - $13,153 due to) a director of the Company which is non-interest bearing, unsecured and due on demand. |
|----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| b)   | As at September 30, 2009, the Company owes $36,673 (December 31, 2008 - $18,119) to shareholders of the Company. The amounts due are non-interest bearing, unsecured and due on demand. |
|----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6.   | Common Stock |
|----------------|--------------|

| a)   | On April 20, 2009, the Company issued 31,250,000 common shares with a fair value of $81,257 for the purchase of the rights, title, and interest in medical intellectual property pursuant to an asset purchase agreement. Refer to Note 4. |
|----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| b)   | On April 24, 2009, the authorized share capital of the company was increased from 65,000,000 shares, par value of US$0.001, to 990,000,000 shares, par value US$0.00001. The share capital and additional paid-in capital amounts have been retroactively adjusted for all periods to reflect this change. |
|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| c)   | On July 13, 2009, the Company completed a 125-for-1 forward stock split of the issued and outstanding common stock. All share amounts have been retroactively adjusted for all periods presented. |
|----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| d)   | On July 20, 2009, a director and former officer of the Company returned 23,953,875 shares of common stock of the Company in exchange for the net liabilities of the Company’s travel business operations effective July 1, 2009 pursuant to an Asset Purchase Agreement dated April 20, 2009. The net liabilities assumed of $12,753 were recorded as additional paid-in capital. |
|----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.   | Subsequent Events |
|----------------|-------------------|

----

Table of Contents

Item 

----

Table of Contents

----

Table of Contents

| ·   | A press release announcing the appointment of our CEO, Aaron Whiteman, incorrectly stated that he was a graduate of the London School of Economics.  Mr. Whiteman is a graduate of Oxford University and did not attend the London School of Economics.  In addition, the press release stated that Mr. Whiteman had “worked with” various listed companies.  Mr. Whiteman has not worked for or directly with the companies listed in the press release. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | A press release regarding the company’s prostaganin-based cancer treatment stated that the company “filed a patent.”   The company filed a patent application, which remains pending.  No patent has been issued.  The press release also states that licensing to various companies “could prove to be extremely lucrative.”  This statement was speculative in nature; no licensing agreements with the listed companies are or were in place. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | A press release related to Dr. Anders Boegh Jensen stated that he had joined the company’s Scientific Advisory Board.  Dr. Jensen is the inventor of our patent-pending drugs and a co-applicant with the company for patents on the drugs in the United Kingdom. Although the company had planned for Dr. Jenson to assist with continuing development of its cancer treatments, he ultimately severed ties with the company. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | A press release inaccurately stated that the company was “aggressively acquiring patents” and has “filed patents” for certain cancer-fighting therapies.  The company acquired certain Danish patent applications and subsequently filed British patent applications for the same inventions.  The applications remain pending and no patents have been issued.  The press release also states that the company “could expect up to $100 million” during clinical trials and “$400 million per annum in the years following commercialization.”  This statement was intended as calculation of the total potential market for a type of prostate-cancer testing that would use the company’s patent-pending intellectual property.  Any suggestion that the company expected or projected total revenues in the amount stated was neither intended nor authorized. |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | A press release announced that Dr. Philip Gould was appointed to the company’s Scientific Advisory Board.  Following service of the subpoena and commencement of the SEC investigation discussed above, Dr. Gould severed ties with the company. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | A press release announced that the company was “preparing for patent application filings” in the U.S. and the E.U. for its prostaganin-based invention.  No patent applications were filed in the U.S. or the E.U. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | A press release announcing the company’s letter of intent with Prime Bioresearch, Inc. also refers to the company’s “expectations of reaching 100m+ revenue in year 3.”  This statement reflects the company’s internal calculation of the total potential market for a type of prostate-cancer testing that would use the company’s patent-pending intellectual property.  Any suggestion that the company expected or projected total revenues in the amount stated was neither intended nor unauthorized. |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

| ·   | A press release announced that the company had signed an engagement with Pacific Wave Partners Limited for the raising of $5 million.  Although a term sheet was entered into by the company and Pacific Wave, the planned financing did not go forward following the trading suspension and SEC investigation discussed above. |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | A press release announced that the company had signed an agreement with Bridge BioResearch Plc.  Although a letter of intent was received from the Chairman of Bridge BioResearch, the CEO of that company later stated that the letter was issued without proper authority and retracted it. |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | A press release announced that a collaboration agreement had been signed by the company and Beckpharma, Ltd.  Although a letter of intent was received from Beckpharma, it was later withdrawn. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ·   | A press release announced that the company was in “advanced negotiations” to acquire patents from TheraGlass, Ltd.  No agreement was concluded with that company. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

----

Table of Contents

Item 

Item 

----

Table of Contents

Item 

Item 

Item 

Item 

Item 

Item 

Item 

| Exhibit  Number | Description of Exhibit                                                                                                                                                        |
|---------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 31.1                      | Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002                             |
| 31.2                      | Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002                             |
| 32.1                      | Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |

----

Table of Contents

|   | Genova Biotherapeutics, Inc.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Date:  | April 16, 2010                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|   | By:        /s/ Aaron Whiteman                                                               Aaron WhitemanTitle:    Chief Executive Officer and Chief Financial Officer |